Randomized Trials, Statistics, and Clinical Inference
Gregg W. Stone, MD*,* and
Stuart J. Pocock, PhD
* Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
London School of Hygiene and Tropical Medicine, London, United Kingdom
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Comparative Mortality Rates for DES and BMS in Acute Myocardial Infarction
(A) Two-year mortality among 1,298 propensity-matched pairs of patients with ST-segment elevation myocardial infarction treated at physician discretion with either paclitaxel or sirolimus drug-eluting stents (DES) or bare-metal stents (BMS) at 21 Massachusetts hospitals. Significantly lower mortality was present with DES, mostly by 30 days, a time before any known benefits of DES compared with BMS. This finding may well be due to residual confounding by unmeasured variables in this nonrandomized study. Adapted from Mauri et al. (2). (B) One-year mortality among 3,006 patients with ST-segment elevation myocardial infarction randomly allocated in a 3:1 ratio to either paclitaxel-eluting stents (PES) or BMS at 123 hospitals in 11 countries. Mortality rates with DES and BMS were nearly identical at 30 days and 1 year. Adapted from Stone et al. (3).
|
|
|
